gtr2 Antibody

What is GTR2 and why are antibodies against it important for research?

GTR2 (also known as RRAGC in humans) is a critical GTPase involved in amino acid-sensing pathways that regulate TORC1 activity. GTR2 forms a heterodimeric complex with GTR1, serving as the yeast homolog of the mammalian RagA-RagC complex that relays amino acid signals to TORC1 . Antibodies against GTR2 are essential research tools that enable the investigation of nutrient-sensing pathways, autophagy regulation, and metabolic processes in various model organisms. These antibodies facilitate the detection, isolation, and characterization of GTR2-containing protein complexes that play fundamental roles in cellular homeostasis and disease pathways.

What species reactivity is available for GTR2 antibodies?

GTR2 antibodies are available with reactivity against multiple species, allowing for comparative studies across different experimental models. Current antibody options include those with reactivity against human, mouse, and rat GTR2 proteins . Some antibodies demonstrate cross-reactivity with hamster GTR2 as well . When selecting an antibody for your research, it is crucial to verify the specific reactivity pattern of each product, as this can vary significantly between manufacturers and even between different catalog numbers from the same supplier.

What applications are GTR2 antibodies validated for?

GTR2 antibodies have been validated for numerous experimental applications, including:

• Western Blotting (WB): For detection of GTR2 protein in cell or tissue lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of GTR2

• Immunohistochemistry (IHC): For visualization of GTR2 in tissue sections

• Immunofluorescence (IF): Including both cellular (cc) and paraffin (p) applications

• Immunoprecipitation (IP): For isolation of GTR2-containing complexes

The selection of antibody should be guided by the specific application requirements, as not all antibodies perform equally across all techniques. For example, the antibody with catalog number ABIN7263499 is validated for IHC and IF applications with reactivity against human, mouse, and rat samples, while ABIN2452103 is validated for WB and IF with reactivity against hamster, human, and mouse samples .

How does the nucleotide-binding status of GTR2 affect antibody recognition?

The nucleotide-binding status of GTR2 (GTP-bound versus GDP-bound) can significantly alter the protein's conformation, potentially affecting epitope accessibility and antibody recognition. The crystal structure of the Gtr1p-Gtr2p complex reveals that nucleotide exchange alters the surface features of switch I and II regions . When designing experiments involving GTR2 antibodies, researchers should consider whether their antibody recognizes epitopes near these conformationally variable regions.

For applications requiring detection of specific nucleotide-bound states of GTR2, researchers might need to employ specialized antibodies that selectively recognize either the GTP-bound (active) or GDP-bound (inactive) conformations. Current structural data indicates that the G domain of GTR2 undergoes significant conformational changes upon nucleotide binding, which may expose or obscure certain epitopes depending on the activation state of the protein .

What role does the GTR1-GTR2 heterodimer play in TORC1 signaling, and how can antibodies help elucidate this interaction?

The GTR1-GTR2 heterodimer (yeast homolog of RagA-RagC) serves as a critical mediator in transmitting amino acid signals to TORC1. Based on structural studies, the heterodimer forms through a unique edge-to-edge arrangement of their C-terminal domains (CTDs), creating a compact three-layered structure . The dimerization is mediated by a network of hydrogen bonds and hydrophobic interactions, with the interface residues being highly conserved from yeast to mammals .

Antibodies against GTR2 can be instrumental in:

• Co-immunoprecipitation experiments to identify novel interaction partners

• Proximity ligation assays to visualize GTR2-GTR1 interactions in situ

• Chromatin immunoprecipitation studies if GTR2 has nuclear functions

• Pull-down assays to assess the impact of mutations on complex formation

When studying the heterodimer, it's important to note that the nucleotide-binding status of GTR1 (RagA in mammals) appears to be the primary determinant of raptor binding and TORC1 activation, while the nucleotide-binding status of GTR2 (RagC in mammals) has a more modest influence .

How can researchers validate GTR2 antibody specificity in their experimental system?

Antibody specificity is a critical concern in research reproducibility, with an estimated $1 billion wasted annually on non-specific antibodies . To validate GTR2 antibody specificity, researchers should implement a multi-faceted approach:

• Knockout/knockdown validation: The gold standard for antibody validation involves testing antibodies in cells where GTR2 has been knocked out (e.g., using CRISPR-Cas9) or knocked down (e.g., using siRNA) . The absence of signal in these negative controls strongly supports antibody specificity.

• Recombinant protein controls: Testing antibodies against purified recombinant GTR2 protein can help establish baseline reactivity and potential cross-reactivity with related proteins.

• Orthogonal method verification: Results obtained with antibodies should be verified using independent methods, such as mass spectrometry or RNA expression analysis.

• Cross-platform consistency: Consistency of results across different applications (e.g., WB, IF, IHC) increases confidence in antibody specificity.

The YCharOS initiative, a collaborative effort between academic and industry scientists, offers standardized characterization of antibodies across multiple applications, providing researchers with independent validation data for commercial antibodies .

What are the optimal conditions for Western blotting with GTR2 antibodies?

Successful Western blotting with GTR2 antibodies requires careful optimization of several parameters:

Sample preparation:

• Use fresh samples when possible or store at -80°C with protease inhibitors

• Include phosphatase inhibitors if studying phosphorylation states of GTR2 or interacting proteins

• Optimize lysis buffer composition based on cellular compartment (GTR2 functions in cytoplasm and at lysosomal membranes)

Blotting conditions:

• Transfer efficiency: Use PVDF membranes for optimal protein retention

• Blocking: 5% non-fat milk or BSA in TBST (may need optimization based on specific antibody)

• Primary antibody dilution: Typically 1:500 to 1:2000 (refer to specific antibody datasheet)

• Secondary antibody selection: Match to host species of primary antibody

• Detection method: Chemiluminescence offers good sensitivity for most applications

Controls:

• Positive control: Lysate from cells known to express GTR2 (e.g., HEK293 for human GTR2)

• Negative control: Lysate from GTR2 knockout cells or tissues

• Loading control: Antibody against housekeeping protein (e.g., GAPDH, actin)

Remember that optimal conditions may vary between different GTR2 antibodies, so preliminary optimization experiments are recommended when using a new antibody.

How can researchers optimize immunofluorescence experiments with GTR2 antibodies?

Immunofluorescence (IF) with GTR2 antibodies requires careful attention to fixation, permeabilization, and antibody incubation conditions:

Cell preparation and fixation:

• Cells should be grown on appropriate substrates (e.g., poly-L-lysine coated coverslips)

• Fixation method affects epitope accessibility: 4% paraformaldehyde (PFA) preserves structure but may mask some epitopes; methanol provides greater permeabilization but can denature some proteins

• For GTR2, which associates with lysosomes when active, PFA fixation is generally preferred

Antibody incubation:

• Blocking: 5-10% normal serum (matching secondary antibody host) with 0.1-0.3% Triton X-100

• Primary antibody dilution: Typically 1:100 to 1:500 for IF applications

• Incubation time: Overnight at 4°C often yields optimal signal-to-noise ratio

• Secondary antibody selection: Choose fluorophores compatible with available microscopy setup

Imaging considerations:

• Include DAPI or Hoechst staining for nuclear visualization

• Consider co-staining with lysosomal markers (e.g., LAMP1) to assess GTR2 localization

• Use appropriate controls for autofluorescence and non-specific binding

Antibodies specifically validated for IF applications, such as ABIN7263499 and ABIN2452103, should be prioritized for these experiments .

What strategies can be employed for co-immunoprecipitation of GTR2-containing complexes?

Co-immunoprecipitation (co-IP) is valuable for studying GTR2 interactions with GTR1 and other proteins in the amino acid sensing pathway:

Lysis conditions:

• Use gentle lysis buffers (e.g., 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) to preserve protein-protein interactions

• Include protease and phosphatase inhibitors

• Consider adding nucleotide stabilizers (e.g., GTPγS or GDP) to preserve specific nucleotide-bound states

Immunoprecipitation protocol:

• Pre-clear lysate with protein A/G beads to reduce non-specific binding

• Incubate cleared lysate with GTR2 antibody (2-5 μg per mg of protein)

• Add protein A/G beads and incubate (4°C, 3-4 hours or overnight)

• Wash beads 3-5 times with lysis buffer

• Elute bound proteins with SDS sample buffer

Analysis of co-precipitated proteins:

• Western blotting for known interactors (e.g., GTR1, TORC1 components)

• Mass spectrometry for unbiased identification of interaction partners

• Always include control IPs with non-specific IgG

When studying the GTR1-GTR2 complex, consider that the interaction with raptor (mTORC1 component) is primarily determined by the nucleotide loading status of GTR1, though GTR2's nucleotide status also modestly influences this interaction .

What are common issues with GTR2 antibody specificity and how can they be addressed?

Specificity issues are a major concern with antibodies in general, with an estimated 30-50% of commercial antibodies having specificity problems . For GTR2 antibodies specifically, researchers should be aware of these common issues:

Cross-reactivity with related proteins:
GTR2/RRAGC belongs to the Rag family of GTPases, which includes closely related proteins like RRAGA, RRAGB, and RRAGD. Antibodies may cross-react with these homologs, particularly if the epitope is in a conserved region.

Solution: Test antibodies in systems where GTR2 is specifically knocked out while related proteins remain expressed. The YCharOS initiative compares antibodies in side-by-side testing using knockout cell lines .

Batch-to-batch variability:
Polyclonal antibodies can exhibit significant variability between production batches, affecting experimental reproducibility.

Solution: When possible, use monoclonal antibodies or recombinant antibodies, which offer greater consistency. If using polyclonal antibodies, purchase larger amounts of a single batch for long-term studies.

Non-specific binding:
Some antibodies may bind to unrelated proteins that share similar epitope structures.

Solution: Always include appropriate negative controls and validate with multiple techniques. Consider multiple antibodies targeting different epitopes of GTR2 to confirm findings.

How can researchers quantitatively assess GTR2 expression across different experimental conditions?

Accurate quantification of GTR2 expression requires consideration of several methodological aspects:

Western blot quantification:

• Use a standard curve with recombinant GTR2 protein for absolute quantification

• Ensure linear range of detection by testing multiple sample dilutions

• Normalize to appropriate loading controls

• Use digital image analysis software for densitometry

ELISA-based quantification:

• Select antibodies specifically validated for ELISA applications

• Include standard curves with recombinant protein

• Account for matrix effects by preparing standards in sample buffer

• Consider sandwich ELISA with two different antibodies for improved specificity

qPCR correlation:

• Compare protein levels (antibody-based) with mRNA levels (qPCR)

• Discrepancies may indicate post-transcriptional regulation

• Include reference genes for normalization

When comparing GTR2 expression across different conditions, always process and analyze samples simultaneously to minimize technical variability.

What considerations are important when studying post-translational modifications of GTR2?

GTR2/RRAGC undergoes various post-translational modifications that regulate its function within the amino acid sensing pathway. When studying these modifications:

Phosphorylation analysis:

• Use phosphatase inhibitors during sample preparation

• Consider phospho-specific antibodies if available

• Complement antibody-based detection with mass spectrometry

• Use Phos-tag gels for mobility shift assays

GTP/GDP binding status:

• The nucleotide binding status of GTR2 affects its conformation and function

• Consider proximity ligation assays to detect specific GTR2 interactions in different nucleotide-bound states

• Structural studies indicate that nucleotide exchanges alter the surface features of switch I and II regions

Subcellular localization:

• GTR2 localization is dynamically regulated by amino acid availability

• Use subcellular fractionation followed by Western blotting

• Combine with immunofluorescence using compartment-specific markers

When studying how mutations affect GTR2 function, consider that the dimerized C-terminal domains (CTDs) of GTR1 and GTR2 form a compact three-layered structure, with dimerization mediated by a network of hydrogen bonds and hydrophobic interactions .

How are computational approaches enhancing antibody specificity determination for targets like GTR2?

Recent advances in computational modeling are transforming antibody research, including potential applications for GTR2 antibody development:

Biophysics-informed modeling:
Modern computational approaches integrate experimental data with biophysical modeling to predict antibody-antigen interactions with unprecedented accuracy. These models can identify distinct binding modes associated with specific ligands, enabling the prediction and generation of antibody variants with customized specificity profiles .

High-throughput sequencing integration:
By combining phage display experiments with high-throughput sequencing and computational analysis, researchers can achieve additional control over antibody specificity profiles. This approach allows for the design of antibodies that either specifically target a particular ligand or demonstrate cross-specificity for multiple targets .

Application to GTR2 research:
For GTR2, these computational approaches could enable the development of antibodies that:

• Specifically recognize GTR2 without cross-reactivity to related Rag GTPases

• Selectively bind to specific conformational states (GTP-bound vs. GDP-bound)

• Target specific protein-protein interaction interfaces

The combination of biophysics-informed modeling and extensive selection experiments offers powerful tools for designing proteins with desired physical properties that extend beyond antibodies .

What role does the GTR1-GTR2 complex structure play in designing conformation-specific antibodies?

The crystal structure of the Gtr1p-Gtr2p complex provides valuable insights for designing antibodies that selectively recognize specific conformational states:

Structural insights:
The GTR1-GTR2 heterodimer forms through an edge-to-edge arrangement of their β sheets in the C-terminal domains (CTDs). The dimerized CTDs create a compact three-layered structure with a 10-stranded anti-parallel β sheet sandwiched between α helices . This unique architecture presents several potential epitopes for antibody targeting.

Conformation-dependent epitopes:

• The P loop, switch I, and switch II regions undergo significant conformational changes upon nucleotide binding

• The surface area containing α1, α2 and β2, β3 of the G domain is important for raptor binding and TORC1 activation

• These regions represent potential targets for conformation-specific antibodies

Application strategies:
Researchers aiming to develop conformation-specific antibodies for GTR2 should:

• Focus immunization or selection strategies on peptides or proteins locked in specific conformations

• Screen candidates against both GTP-bound and GDP-bound forms to identify state-specific binders

• Validate specificity using mutants locked in specific conformational states

By targeting conformation-specific epitopes, researchers can develop tools to dissect the dynamic regulation of GTR2 in amino acid sensing and TORC1 activation.

How is the Open Science movement influencing antibody validation for targets like GTR2?

The Open Science movement is transforming antibody research through collaborative initiatives that address reproducibility challenges:

YCharOS initiative:
The YCharOS (Antibody Characterization through Open Science) platform represents a groundbreaking collaboration between academic researchers and major antibody manufacturers. This initiative evaluates antibody specificity through standardized characterization processes, including knockout cell lines and side-by-side testing across key applications .

Impact on GTR2 research:
For GTR2 researchers, such initiatives provide:

• Independent validation data for commercial antibodies

• Standardized protocols for antibody characterization

• Comparative information across different manufacturers' products

The collaborative approach exemplified by YCharOS, which has already tested approximately 1,200 antibodies against 120 protein targets, demonstrates how industry competitors can work together to advance scientific reproducibility . Similar approaches applied to GTR2 antibodies would significantly enhance research quality in this field.

What emerging technologies might revolutionize GTR2 detection and functional analysis?

Several cutting-edge technologies hold promise for advancing GTR2 research beyond traditional antibody applications:

Nanobodies and single-domain antibodies:
These smaller antibody fragments offer improved tissue penetration and can access epitopes that conventional antibodies cannot reach. For GTR2, which functions in protein complexes, nanobodies might access epitopes that are sterically hindered in traditional antibody approaches.

Proximity-dependent labeling:
BioID or APEX2-based approaches enable the identification of proteins in close proximity to GTR2 in living cells, providing insights into its dynamic interactome under different conditions.

Intracellular antibody fragments:
Expressing antibody fragments inside cells (intrabodies) could allow real-time monitoring of GTR2 conformational changes or inhibition of specific interactions.

CRISPR-based tagging:
Endogenous tagging of GTR2 using CRISPR-Cas9 enables visualization and purification of physiologically relevant complexes without overexpression artifacts.

As these technologies continue to develop, they will complement traditional antibody-based approaches and provide deeper insights into GTR2 function in nutrient sensing and cellular metabolism.